// App-Quantinova.ai

CT558 : Capmatinib vs docetaxel as second- or third-line therapy in patients with locally advanced or metastatic METex14-mutated NSCLC: The GeoMETry-III trial

Researchers

Presenter

  • Pierre Jean Souquet

Principal Investigators

  • Sang-We Kim

  • Johan F. Vansteenkiste

  • Anna Robeva

  • Aline Jary

  • Sabine Glaser

  • Alejandro Yovine

  • Juergen Wolf

Medical Centers

  • Department of Thoracic Oncology, University Hospital of Lyon-Sud, Pierre-Bénite, Lyon, France

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

  • Respiratory Oncology Unit (Pulmonology), University Hospital KU Leuven, Leuven, Belgium

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Oncology Clinical Development, Novartis Pharma AG, Basel, Switzerland

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Capmatinib

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Cross Over

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT04427072

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved